The Signosis TL1A/DR3 NF-κB Luciferase Reporter Jurkat Stable Cell Line is a genetically engineered T-cell reporter model designed for sensitive, quantitative evaluation of TL1A–DR3 signaling and downstream NF-κB transcriptional activation.
 
This stable cell line was developed by introducing human Death Receptor 3 (DR3, also known as TNFRSF25), the functional receptor for TNF-like ligand 1A (TL1A/TNFSF15), into the Signosis NF-κB Luciferase Reporter Jurkat Cell Line using lentiviral transduction.
 
Upon TL1A binding to DR3, intracellular signaling activates the NF-κB pathway, resulting in increased firefly luciferase expression. The resulting bioluminescent signal provides a convenient and quantitative readout of TL1A-induced cellular signaling.
 
The reporter cell line is particularly suitable for studying the TL1A–DR3 signaling axis, evaluating therapeutic inhibitors and neutralizing antibodies, and supporting drug discovery programs targeting inflammatory and autoimmune diseases.